174 related articles for article (PubMed ID: 12827272)
21. [Repair of the splicing defect of thalassemic allele beta IVS-2-654 C-->T in cultured human erythroid cells by antisense RNA].
Gu X; Gong L; Zhang W
Zhonghua Yi Xue Za Zhi; 1997 Nov; 77(11):815-8. PubMed ID: 9772473
[TBL] [Abstract][Full Text] [Related]
22. Molecular correction of Duchenne muscular dystrophy by splice modulation and gene editing.
Hanson B; Wood MJA; Roberts TC
RNA Biol; 2021 Jul; 18(7):1048-1062. PubMed ID: 33472516
[TBL] [Abstract][Full Text] [Related]
23. Target selection for antisense oligonucleotide induced exon skipping in the dystrophin gene.
Errington SJ; Mann CJ; Fletcher S; Wilton SD
J Gene Med; 2003 Jun; 5(6):518-27. PubMed ID: 12797117
[TBL] [Abstract][Full Text] [Related]
24. Antisense modulation of both exonic and intronic splicing motifs induces skipping of a DMD pseudo-exon responsible for x-linked dilated cardiomyopathy.
Rimessi P; Fabris M; Bovolenta M; Bassi E; Falzarano S; Gualandi F; Rapezzi C; Coccolo F; Perrone D; Medici A; Ferlini A
Hum Gene Ther; 2010 Sep; 21(9):1137-46. PubMed ID: 20486769
[TBL] [Abstract][Full Text] [Related]
25. Correction of aberrant pre-mRNA splicing by antisense oligonucleotides in beta-thalassemia Egyptian patients with IVSI-110 mutation.
El-Beshlawy A; Mostafa A; Youssry I; Gabr H; Mansour IM; El-Tablawy M; Aziz M; Hussein IR
J Pediatr Hematol Oncol; 2008 Apr; 30(4):281-4. PubMed ID: 18391696
[TBL] [Abstract][Full Text] [Related]
26. Chimeric snRNA molecules carrying antisense sequences against the splice junctions of exon 51 of the dystrophin pre-mRNA induce exon skipping and restoration of a dystrophin synthesis in Delta 48-50 DMD cells.
De Angelis FG; Sthandier O; Berarducci B; Toso S; Galluzzi G; Ricci E; Cossu G; Bozzoni I
Proc Natl Acad Sci U S A; 2002 Jul; 99(14):9456-61. PubMed ID: 12077324
[TBL] [Abstract][Full Text] [Related]
27. Antisense oligonucleotide induced dystrophin exon 45 skipping at a low half-maximal effective concentration in a cell-free splicing system.
Malueka RG; Yagi M; Awano H; Lee T; Dwianingsih EK; Nishida A; Takeshima Y; Matsuo M
Nucleic Acid Ther; 2011 Oct; 21(5):347-53. PubMed ID: 21967521
[TBL] [Abstract][Full Text] [Related]
28. Systematic evaluation of 2'-Fluoro modified chimeric antisense oligonucleotide-mediated exon skipping in vitro.
Chen S; Le BT; Chakravarthy M; Kosbar TR; Veedu RN
Sci Rep; 2019 Apr; 9(1):6078. PubMed ID: 30988454
[TBL] [Abstract][Full Text] [Related]
29. Antisense oligonucleotide modulation of non-productive alternative splicing upregulates gene expression.
Lim KH; Han Z; Jeon HY; Kach J; Jing E; Weyn-Vanhentenryck S; Downs M; Corrionero A; Oh R; Scharner J; Venkatesh A; Ji S; Liau G; Ticho B; Nash H; Aznarez I
Nat Commun; 2020 Jul; 11(1):3501. PubMed ID: 32647108
[TBL] [Abstract][Full Text] [Related]
30. Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides.
Dominski Z; Kole R
Proc Natl Acad Sci U S A; 1993 Sep; 90(18):8673-7. PubMed ID: 8378346
[TBL] [Abstract][Full Text] [Related]
31. Splice-switching antisense oligonucleotides as therapeutic drugs.
Havens MA; Hastings ML
Nucleic Acids Res; 2016 Aug; 44(14):6549-63. PubMed ID: 27288447
[TBL] [Abstract][Full Text] [Related]
32. DMD pseudoexon mutations: splicing efficiency, phenotype, and potential therapy.
Gurvich OL; Tuohy TM; Howard MT; Finkel RS; Medne L; Anderson CB; Weiss RB; Wilton SD; Flanigan KM
Ann Neurol; 2008 Jan; 63(1):81-9. PubMed ID: 18059005
[TBL] [Abstract][Full Text] [Related]
33. Modification of alternative splicing by antisense oligonucleotides as a potential chemotherapy for cancer and other diseases.
Mercatante DR; Sazani P; Kole R
Curr Cancer Drug Targets; 2001 Nov; 1(3):211-30. PubMed ID: 12188880
[TBL] [Abstract][Full Text] [Related]
34. Antisense oligonucleotides and RNAs as modulators of pre-mRNA splicing.
Sierakowska H; Gorman L; Kang SH; Kole R
Methods Enzymol; 2000; 313():506-21. PubMed ID: 10595376
[No Abstract] [Full Text] [Related]
35. Sensitivity of splice sites to antisense oligonucleotides in vivo.
Sierakowska H; Sambade MJ; Schümperli D; Kole R
RNA; 1999 Mar; 5(3):369-77. PubMed ID: 10094306
[TBL] [Abstract][Full Text] [Related]
36. RNA Therapeutics: How Far Have We Gone?
Coutinho MF; Matos L; Santos JI; Alves S
Adv Exp Med Biol; 2019; 1157():133-177. PubMed ID: 31342441
[TBL] [Abstract][Full Text] [Related]
37. Deletion of individual exons and induction of soluble murine interleukin-5 receptor-alpha chain expression through antisense oligonucleotide-mediated redirection of pre-mRNA splicing.
Karras JG; McKay RA; Dean NM; Monia BP
Mol Pharmacol; 2000 Aug; 58(2):380-7. PubMed ID: 10908306
[TBL] [Abstract][Full Text] [Related]
38. Antisense oligonucleotides as modulators of pre-mRNA splicing.
Sierakowska H; Agrawal S; Kole R
Methods Mol Biol; 2000; 133():223-33. PubMed ID: 10561842
[No Abstract] [Full Text] [Related]
39. Designing Effective Antisense Oligonucleotides for Exon Skipping.
Shimo T; Maruyama R; Yokota T
Methods Mol Biol; 2018; 1687():143-155. PubMed ID: 29067661
[TBL] [Abstract][Full Text] [Related]
40. RNA splicing manipulation: strategies to modify gene expression for a variety of therapeutic outcomes.
Wilton SD; Fletcher S
Curr Gene Ther; 2005 Oct; 5(5):467-83. PubMed ID: 16250888
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
